2023
DOI: 10.5603/dk.a2023.0001
|View full text |Cite
|
Sign up to set email alerts
|

The Promise of Diabetes Technologies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(5 citation statements)
references
References 19 publications
0
3
0
Order By: Relevance
“…Furthermore, it is noteworthy that both the prevalence and incidence of T1D among racial and ethnic minority groups are increasing 42,43 . At present, underserved people with T1D are less likely to use technologies such as continuous glucose monitoring (CGM) and insulin pump therapy 44,45 . There are numerous contributors to the digital divide in T1D, 46–54 as illustrated in Figure 3.…”
Section: Improving Access To Digital Health Technologies For People W...mentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, it is noteworthy that both the prevalence and incidence of T1D among racial and ethnic minority groups are increasing 42,43 . At present, underserved people with T1D are less likely to use technologies such as continuous glucose monitoring (CGM) and insulin pump therapy 44,45 . There are numerous contributors to the digital divide in T1D, 46–54 as illustrated in Figure 3.…”
Section: Improving Access To Digital Health Technologies For People W...mentioning
confidence: 99%
“… 42 , 43 At present, underserved people with T1D are less likely to use technologies such as continuous glucose monitoring (CGM) and insulin pump therapy. 44 , 45 There are numerous contributors to the digital divide in T1D, 46 54 as illustrated in Figure 3 .…”
Section: Improving Access To Digital Health Technologies For People W...mentioning
confidence: 99%
“…It is indeed unfortunate that the more widespread use of these valuable technologies is limited by socioeconomic inequalities ( Bellary et al, 2012 ; Scott et al, 2017 ; Alcantara-Aragon, 2019 ; Fauzi et al, 2022 ; Mishra et al, 2022 ). Novel diabetes technologies for assessing glucose levels can be classified (broadly) into three tiers; 1) CGM (or flash/intermittent monitors), 2) CGM with sensor augmented insulin pump, and 3) automated insulin delivery systems ( Ebekozien and Shah, 2023 ). Although these technological advances have unquestionably helped to improve glycemic control and reduce that incidence of severe hypoglycemia in people with T1D, the extent to which these technologies can restore awareness of hypoglycemia remains an active area of investigation ( Choudhary et al, 2013 ; Little et al, 2014 ; van Beers et al, 2016 ; Heinemann et al, 2018 ; Rickels et al, 2018 ; Cook et al, 2019 ; Lin et al, 2019 ; Lin et al, 2020b ; Pratley et al, 2020 ; Sepulveda et al, 2020 ; Burckhardt et al, 2021 ; Bahrami et al, 2022 ; Takagi et al, 2022b ).…”
Section: Impaired Awareness Of Hypoglycemia (Iah) Therapiesmentioning
confidence: 99%
“…Novel diabetes technologies for assessing glucose levels can be classified (broadly) into three tiers; 1) CGM (or flash/intermittent monitors), 2) CGM with sensor augmented insulin pump, and 3) automated insulin delivery systems (Ebekozien and Shah, 2023).…”
Section: Technologymentioning
confidence: 99%
See 1 more Smart Citation